Merck KGaA, which has enabled important cost efficiencies and record go-to-market timelines for COVID-19 vaccines globally, is doubling down on plans for its messenger RNA (mRNA) offerings and single-use technologies.
While the German group already collaborates with frontline mRNA players and has long-standing experience in producing lipids - one of the key components for the formulation of mRNA therapeutics, including...
In an interview with Scrip, Benoit Opsomer, vice-president and head of bioprocessing, Asia Pacific, Merck Life Science, outlined how the company was building on core strengths and adding new capabilities,...